Embed
Pune s Mylab received Indian Council of Medical Research (ICMR) approval for India s first self-use Rapid Antigen Test kit CoviSelf for Covid-19. This test is for self-use. If you test positive via this there s no need for RT-PCR test as per ICMR. Any adult can use this kit by reading our manual, said Sujit Jain, Mylab’s Director (Corporate Strategy).
Covid-19 cases in less than 2% of population, says govt
Mirror Online / Updated: May 19, 2021, 07:43 IST
India s Covid-19 cases account for less than 2% of the population, indicating
containment measures have worked to keep the spread under control as compared to many other countries where the share of the affected population is much higher, the government said.
At the same time, the government said this meant 98% of the population was still vulnerable and susceptible to infection, emphasising on the need to continue stringent containment measures and Covid-appropriate behaviour.
The
health ministry s formulation at a media briefing on Tuesday raised eyebrows as the claim that 98% of the population is vulnerable seemed to assume the incidence of Covid-19 infections was strictly limited to the 2.5 crore cases reported so far. The claim ignored the finding of the national sero-survey that one-fifth of the population was exposed to the disease.
Representative image
NEW DELHI: The government on Monday dropped the use of convalescent plasma therapy for treating Covid patients from Clinical Management Guidelines.
Last week, the ICMR-National Task Force for Covid-19 held a meeting in which all the members were in favour of removing the use of convalescent plasma from the guidelines, citing its ineffectiveness and inappropriate use in several cases.
An Indian Council of Medical Research (ICMR) official said the task force revised the Clinical Guidance for Management of Adult Covid-19 Patients and dropped convalescent plasma (off label) .
The decision to remove it from the guidelines comes in the backdrop of some clinicians and scientists writing to Principal Scientific Advisor K VijayRaghavan cautioning against the irrational and non-scientific use of convalescent plasma for Covid-19 in the country.
India News: Amid rising concerns about new SARS-CoV2 variants and a surge in Covid-19 cases, the government plans to add 17 laboratories to the INSACOG (Indian SA
NEW DELHI: A national tracking platform will be established soon to determine the impact of the jabs against Covid-19 and the breakthrough infections that are likely to occur among those with complete and partial immunisation, official sources said.
The recommendation of the National Technical Advisory Group on Immunisation (NTAGI) to establish such a platform has been accepted by the National Expert Group on Vaccine Administration for Covid-19 and the Union health ministry, they said.
The vaccine tracker will be particularly important to monitor the impact of increasing the dosing schedule of Covishield, he said, as the government on Thursday accepted the working group’s recommendation to extend the gap between the two doses of the Covishield vaccine from six-eight weeks to 12-16 weeks.